OSR (OSRH) FDA Approvals $0.24 -0.01 (-2.83%) As of 10/2/2026 03:59 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings OSR's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by OSR (OSRH). Over the past two years, OSR has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as VXM01. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. VXM01 FDA Regulatory Events VXM01 is a drug developed by OSR for the following indication: patients with recurrent glioblastoma. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Analysis - August 3,2026Analysis Drug: VXM01Announced Date: August 3, 2026Indication: patients with recurrent glioblastoma.AnnouncementOSR Health, Inc. announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.AI SummaryOSR Health, Inc. announced that its subsidiary, Vaximm AG, has completed its analysis of two clinical studies evaluating VXM01 in patients with recurrent glioblastoma. The studies tested the oral DNA vaccine alone and in combination with checkpoint inhibition. VXM01 is designed to activate T cells against VEGFR-2, a protein that helps tumors form new blood vessels and may contribute to immune suppression in the tumor environment. Prof. Wolfgang Wick of Heidelberg University, the trials’ principal investigator, said the results were encouraging and supported further clinical development of the treatment approach. The company plans to submit the findings to a peer-reviewed medical journal once the publication process allows. OSR Health also expects to release additional top-line results and provide more information about the future development of VXM01 and its broader vaccine platform.Read Announcement OSR FDA Events - Frequently Asked Questions Has OSR received FDA approval? As of now, OSR (OSRH) has not received any FDA approvals for its therapy in the last two years. What drugs has OSR submitted to the FDA? In the past two years, OSR (OSRH) has reported FDA regulatory activity for VXM01. What is the most recent FDA event for OSR? The most recent FDA-related event for OSR occurred on August 3, 2026, involving VXM01. The update was categorized as "Analysis," with the company reporting: "OSR Health, Inc. announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma." What conditions do OSR's current drugs treat? Currently, OSR has one therapy (VXM01) targeting the following condition: patients with recurrent glioblastoma.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsInflaRx FDA EventsCentury Therapeutics FDA EventsObsidian Therapeutics FDA EventsSurrozen FDA EventsVera Therapeutics FDA EventsVerastem FDA EventsJohnson & Johnson FDA EventsTeva Pharmaceutical Industries FDA EventsAktis Oncology FDA EventsAgomAb Therapeutics FDA EventsArtiva Biotherapeutics FDA EventsArvinas FDA EventsBioCardia FDA EventsCandel Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Quince Therapeutics FDA Events Sangamo Therapeutics FDA Events Radiopharm Theranostics FDA Events TScan Therapeutics FDA Events Estrella Immunopharma FDA Events Jasper Therapeutics FDA Events Neuphoria Therapeutics FDA Events Akari Therapeutics FDA Events Atossa Genetics FDA Events NextCure FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:OSRH last updated on 8/3/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OSR Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OSR With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Analysis - August 3,2026Analysis Drug: VXM01Announced Date: August 3, 2026Indication: patients with recurrent glioblastoma.AnnouncementOSR Health, Inc. announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.AI SummaryOSR Health, Inc. announced that its subsidiary, Vaximm AG, has completed its analysis of two clinical studies evaluating VXM01 in patients with recurrent glioblastoma. The studies tested the oral DNA vaccine alone and in combination with checkpoint inhibition. VXM01 is designed to activate T cells against VEGFR-2, a protein that helps tumors form new blood vessels and may contribute to immune suppression in the tumor environment. Prof. Wolfgang Wick of Heidelberg University, the trials’ principal investigator, said the results were encouraging and supported further clinical development of the treatment approach. The company plans to submit the findings to a peer-reviewed medical journal once the publication process allows. OSR Health also expects to release additional top-line results and provide more information about the future development of VXM01 and its broader vaccine platform.Read Announcement
Free OSRH Stock Alerts